MiMedx Reports Positive CAMPAIGN Trial Interim Results, Enrollment Ongoing
ByAinvest
Thursday, Nov 13, 2025 8:16 am ET1min read
MDXG--
MiMedx Group has announced the publication of interim results from the CAMPAIGN trial, which demonstrate clinical benefit associated with the use of EPIEFFECT compared to standard of care. The study, published in the International Journal of Tissue Repair, is a randomized controlled trial designed to evaluate the performance of EPIEFFECT in treating nonhealing diabetic foot ulcers. Enrollment for the trial is ongoing, with advanced predictive models indicating superior results for EPIEFFECT.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet